Released : February 13, 2018 07:00 RNS Number : 6464E MaxCyte, Inc. 13 February 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Dr Richard Douglas Joins MaxCyte Board Dr Douglas previously served as Senior Vice President of Corporate Development at Genzyme Gaithersburg, Maryland - 13
Released : February 01, 2018 16:06 RNS Number : 6932D MaxCyte, Inc. 01 February 2018 SCHEDULE 6 AIM BLOCK ADMISSION SIX MONTHLY RETURN Please ensure the entries on this return are typed a. Name of company MaxCyte, Inc. b. Name of scheme(s) MaxCyte Long Term Incentive Plan c.
Released : January 23, 2018 13:32 RNS Number : 6888C MaxCyte, Inc. 23 January 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Total Voting Rights Maryland, USA - 23 January 2018: MaxCyte (LSE: MXCT, MXCR) announces that, following an exercise of options, 18,293 new shares of common
Released : January 22, 2018 07:00 RNS Number : 4641C MaxCyte, Inc. 22 January 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update Gaithersburg, Maryland - 22 January 2018: MaxCyte (LSE: MXCT, MXCR), a US-based global company driving the acceleration of the discovery,
Released : January 12, 2018 17:13 RNS Number : 7976B MaxCyte, Inc. 12 January 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Total Voting Rights Maryland, USA - 12 January 2018: MaxCyte (LSE: MXCT, MXCR) announces that, following an exercise of options, 18,293 new shares of common
Released : November 30, 2017 15:26 RNS Number : 0291Y MaxCyte, Inc. 30 November 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Total Voting Rights Maryland, USA - 30 November 2017: MaxCyte (LSE: MXCT, MXCR) announces that, following an exercise of options, 41,121 new shares of common
Released : October 31, 2017 12:47 RNS Number : 1243V MaxCyte, Inc. 31 October 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Result of AGM Maryland, USA - 31 October 2017: MaxCyte (LSE: MXCT, MXCR), a US-based global company driving the acceleration of the discovery, development,
Released : October 16, 2017 07:00 RNS Number : 6267T MaxCyte, Inc. 16 October 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Declaration of Audit Remuneration Maryland, USA - 16 October 2017: MaxCyte (LSE: MXCT, MXCR), in order to assist investors in considering the resolutions
Released : October 05, 2017 18:32 RNS Number : 8773S MaxCyte, Inc. 05 October 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Released : October 05, 2017 18:31 RNS Number : 8770S MaxCyte, Inc. 05 October 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
